Compare NetFlix Inc (NFLX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? NetFlix Inc trades at $70.85 (market cap $293.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: NetFlix Inc is far larger — about 60.1× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NFLX | TVTX | |
|---|---|---|
Market Cap | $293.39B | $4.88B |
Volume | 27,708,338 | 1,668,577 |
Sector | Media | Health |
52-Week High | $124.13 | $67.52 |
52-Week Low | $67.06 | $26.79 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $298.57B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.61, up 0.44% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.80, beating expectations, and maintains robust profitability with 28.22% net margin and 49.54% ROE. Recent news highlights content expansion into live sports and positive analyst sentiment with a $89.39 consensus price target.
Netflix presents a compelling growth story with expanding margins and strategic content investments, though technical indicators signal near-term caution. The stock offers 27% upside to analyst targets but faces competition and execution risks in live sports expansion.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
